OncoMatch/Clinical Trials/NCT05316935
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Is NCT05316935 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including GnRHa and Letrozole 2.5mg for endometrial neoplasms.
Treatment: GnRHa · Letrozole 2.5mg · Diane-35 · MET — To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Grade: g1
Prior therapy
Must have received: progestin (megestrol acetate, medroxyprogesterone acetate, levonorgestrel intrauterine system (LNG-IUS)) — first-line
Using progestin, any of the following therapy, as first-line treatment: 1. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not 2. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not 3. LNG-IUS inserted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify